Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Drug extends life for lung cancer patients

  • Comment

A drug currently used to treat pancreatic cancer could help women with advanced lung cancer as well, new research has indicated.

Early studies showed that Tarceva was found to extend life in lung cancer patients who are too ill to get any more chemotherapy. The drug was given as a first-line treatment during the research.

An American Society of Clinical Oncology conference in Chicago heard that 15% of female lung cancer sufferers who received Tarceva were alive and there was no aggression of their condition a year later. This compared with 5%of women taking a placebo.

Currently, Tarceva is only used after chemotherapy and only about 7% of lung cancer sufferers in the UK are still alive five years after the disease is diagnosed.

A total of 670 men and women with advanced non-small cell lung cancer took part in the Cancer Research UK trial. Tarceva (also known as erlotinib) works by interfering with how cancer cells multiply.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs